12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga · 05/23 17:06
Gainers
- Imunon (NASDAQ:IMNN) stock rose 152.4% to $1.05 during Friday's regular session. The company's market cap stands at $15.3 million.
- RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 27.6% to $1.09. The market value of their outstanding shares is at $144.8 million.
- ALT5 Sigma (NASDAQ:ALTS) shares rose 19.42% to $8.57. The market value of their outstanding shares is at $149.6 million.
- Lucid Diagnostics (NASDAQ:LUCD) shares rose 17.66% to $1.56. The company's market cap stands at $159.0 million.
- Evotec (NASDAQ:EVO) stock moved upwards by 17.61% to $4.74. The company's market cap stands at $1.6 billion.
- Radiopharm Theranostics (NASDAQ:RADX) shares increased by 15.18% to $4.93. The market value of their outstanding shares is at $38.3 million.
Losers
- Bicara Therapeutics (NASDAQ:BCAX) shares fell 43.0% to $8.93 during Friday's regular session. The company's market cap stands at $487.0 million.
- Conduit Pharmaceuticals (NASDAQ:CDT) shares decreased by 20.81% to $3.25. The market value of their outstanding shares is at $2.5 million.
- Gyre Therapeutics (NASDAQ:GYRE) stock declined by 20.43% to $8.92. The market value of their outstanding shares is at $785.8 million.
- Immix Biopharma (NASDAQ:IMMX) stock decreased by 20.13% to $1.93. The market value of their outstanding shares is at $53.6 million.
- Longevity Health Holdings (NASDAQ:XAGE) stock declined by 19.43% to $2.78. The market value of their outstanding shares is at $2.7 million.
- Onconetix (NASDAQ:ONCO) shares fell 16.61% to $0.07. The company's market cap stands at $1.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.